BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35201264)

  • 1. Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
    Dai WF; Beca JM; Nagamuthu C; Liu N; de Oliveira C; Earle CC; Trudeau M; Chan KKW
    JAMA Oncol; 2022 Apr; 8(4):597-606. PubMed ID: 35201264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.
    Dai WF; Beca JM; Nagamuthu C; Liu N; de Oliveira C; Earle CC; Trudeau M; Mercer RE; Chan KKW
    JAMA Netw Open; 2022 Feb; 5(2):e2145460. PubMed ID: 35226087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
    Cheng LJ; Loke L; Lim EH; Pearce F; Aziz MIA; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):449-456. PubMed ID: 33595372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
    J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
    Leung HWC; Chan ALF; Muo CH; Leung JH
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):207-213. PubMed ID: 28965422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore.
    Lim EH; Lim A; Khara JS; Cheong J; Fong J; Sivanesan S; Griffiths M; New E; Lee SC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):413-426. PubMed ID: 38289042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
    Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
    Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Pandor A; Thokala P; Stevens JW; Kaltenthaler E; Clowes M; Coleman R; Wyld L
    Pharmacoeconomics; 2018 Jan; 36(1):29-38. PubMed ID: 28770452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer.
    Jiao B; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):497-504. PubMed ID: 33645393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
    JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.
    Ethier JL; Desautels D; Robinson A; Amir E; Kong W; Booth CM
    JAMA Oncol; 2021 Sep; 7(9):e212140. PubMed ID: 34236387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
    Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
    JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.